{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42","upperLimit":"99","value":"80"},{"groupId":"OG001","lowerLimit":"64","upperLimit":"99","value":"90"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"Percentage of subjects with neutrophil engraftment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycles of multi-agent chemotherapy within the 3 months previous to umbilical cord blood transplantation.","id":"OG000","title":"No Anti-thymocyte Globulin (ATG)"},{"description":"Hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplantation, should receive Anti-thymocyte Globulin (ATG) as part of their conditioning regimen.","id":"OG001","title":"Anti-thymocyte Globulin (ATG)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Day 42","title":"Neutrophil Engraftment","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}